Septerna (NASDAQ:SEPN) SVP Sells $532,650.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 15,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,423,590.12. The trade was a 13.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Septerna Stock Up 8.1%

NASDAQ SEPN opened at $37.34 on Friday. Septerna, Inc. has a twelve month low of $10.26 and a twelve month high of $37.99. The business has a 50-day moving average price of $29.24 and a 200-day moving average price of $27.36. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -46.10 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last issued its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The company had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Research analysts expect that Septerna, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC lifted its holdings in shares of Septerna by 8.1% in the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after acquiring an additional 100,000 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Septerna by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock valued at $1,411,000 after acquiring an additional 3,377 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Septerna in the first quarter valued at $21,334,000. Swiss National Bank bought a new stake in shares of Septerna in the 1st quarter worth about $531,000. Finally, First Light Asset Management LLC boosted its stake in shares of Septerna by 18.0% during the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after purchasing an additional 112,049 shares during the period.

Wall Street Analyst Weigh In

Several research firms have recently commented on SEPN. Cantor Fitzgerald reissued an “overweight” rating and issued a $60.00 target price on shares of Septerna in a report on Tuesday, March 10th. Wells Fargo & Company lifted their price target on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Stifel Nicolaus initiated coverage on shares of Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Septerna in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.78.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.